Show simple item record

dc.contributor.authorHolmes, Sarah J
dc.contributor.authorWhitehouse, R W
dc.contributor.authorClark, S T
dc.contributor.authorCrowther, Derek
dc.contributor.authorAdams, J E
dc.contributor.authorShalet, Stephen M
dc.date.accessioned2010-04-23T09:53:25Z
dc.date.available2010-04-23T09:53:25Z
dc.date.issued1994-08
dc.identifier.citationReduced bone mineral density in men following chemotherapy for Hodgkin's disease. 1994, 70 (2):371-5 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid8054287
dc.identifier.urihttp://hdl.handle.net/10541/97236
dc.description.abstractWe have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years, with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's disease. Forearm cortical bone mineral content (BMC) and lumbar spine and femoral neck integral BMD were measured 3.4 (1.1-6.8) years after completion of chemotherapy, and results expressed as Z (standard deviation) scores. There was a significant reduction in forearm cortical BMC (median BMC 1.727 g cm-1, median Z-score -0.8, P < 0.0005), in lumbar spine integral BMD (median BMD 1.141 g cm-2, median Z-score -0.6, P < 0.0005) and in femoral neck integral BMD (median BMD 0.991 g cm-2, median Z-score -0.4, P < 0.05). There was no significant correlation between Z-score and time elapsed since completion of chemotherapy, and no significant difference in Z-score according to type of chemotherapeutic regimen or number of cycles of chemotherapy received. In conclusion, men who are in complete remission following treatment of Hodgkin's disease have reduced cortical and trabecular BMD. Possible causes include mild hypogonadism secondary to chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect of high-dose glucocorticoid on bone or an effect of Hodgkin's disease per se.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBone Density
dc.subject.meshEtoposide
dc.subject.meshFollicle Stimulating Hormone
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshLuteinizing Hormone
dc.subject.meshMale
dc.subject.meshMechlorethamine
dc.subject.meshMiddle Aged
dc.subject.meshPrednisolone
dc.subject.meshProcarbazine
dc.subject.meshSex Hormone-Binding Globulin
dc.subject.meshTestosterone
dc.subject.meshVinblastine
dc.titleReduced bone mineral density in men following chemotherapy for Hodgkin's disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractWe have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years, with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's disease. Forearm cortical bone mineral content (BMC) and lumbar spine and femoral neck integral BMD were measured 3.4 (1.1-6.8) years after completion of chemotherapy, and results expressed as Z (standard deviation) scores. There was a significant reduction in forearm cortical BMC (median BMC 1.727 g cm-1, median Z-score -0.8, P < 0.0005), in lumbar spine integral BMD (median BMD 1.141 g cm-2, median Z-score -0.6, P < 0.0005) and in femoral neck integral BMD (median BMD 0.991 g cm-2, median Z-score -0.4, P < 0.05). There was no significant correlation between Z-score and time elapsed since completion of chemotherapy, and no significant difference in Z-score according to type of chemotherapeutic regimen or number of cycles of chemotherapy received. In conclusion, men who are in complete remission following treatment of Hodgkin's disease have reduced cortical and trabecular BMD. Possible causes include mild hypogonadism secondary to chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect of high-dose glucocorticoid on bone or an effect of Hodgkin's disease per se.


This item appears in the following Collection(s)

Show simple item record